Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: biosimilars - PanGen Biotech

Next Previous
Drug Profile

Research programme: biosimilars - PanGen Biotech

Alternative Names: Adalimumab biosimilar - pangen biotech; Bevacizumab biosimilar - pangen biotech; Cetuximab biosimilar - pangen biotech; Etanercept biosimilar - Pangen biotech; Human blood coagulation factor IX - PanGen Biotech; Human blood coagulation factor VIII - PanGen Biotech; Human bone morphogenetic protein-2 - PanGen Biotech; Human bone morphogenetic protein-4 - PanGen Biotech; Human bone morphogenetic protein-7 - PanGen Biotech; Human erythropoietin - PanGen Biotech; Human follicle stimulating hormone - PanGen Biotech; Human granulocyte colony stimulating factor - PanGen Biotech; Human granulocyte macrophage colony stimulating factor - PanGen Biotech; Human growth hormone - PanGen Biotech; Human hepatocyte growth factor - PanGen Biotech; Human interferon-alpha - PanGen Biotech; Human interferon-beta - PanGen Biotech; Human interferon-gamma - PanGen Biotech; Human interleukin-10 - PanGen Biotech; Human interleukin-11 - PanGen Biotech; Human interleukin-12 - PanGen Biotech; Human interleukin-2 - PanGen Biotech; Human interleukin-3 - PanGen Biotech; Human interleukin-4 - PanGen Biotech; Human interleukin-6 - PanGen Biotech; Human luteinizing hormone - PanGen Biotech; Human thrombopoietin - PanGen Biotech; Human thyroid stimulating hormone - PanGen Biotech; Human transforming growth factor beta 3 - PanGen Biotech; Human tumour necrosis factor alpha - PanGen Biotech; Human vascular endothelial growth factor 165 - PanGen Biotech; Infliximab biosimilar- PanGen Biotech; PGA101; PGA102; PGA103; PGA104; PGA105; PGA106; PGA107; PGA109; PGA110; PGA111; PGA112; PGA113; PGA114; PGA115; PGA116; PGA117; PGA118; PGA119; PGA120; PGA131; PGB202; PGB204; PGB205; PGC301; PGC302; PGC303; PGC304; PGC305; PGF602; PGF603; PGF604; PGF605; PGF606; PGF607; PGF608; Rituximab biosimilar - PanGen Biotech; Trastuzumab biosimilar - PanGen Biotech

Latest Information Update: 28 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PanGen Biotech
  • Class Blood coagulation factors; Colony-stimulating factors; Follicle stimulating hormones; Glycoproteins; Growth factors; Monoclonal antibodies; Pituitary gonadotropins; Recombinant fusion proteins; Recombinant proteins; Transforming growth factors
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; B cell inhibitors; B cell stimulants; Blood coagulation factor replacements; CD20 antigen inhibitors; Colony-stimulating factor replacements; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Erythropoiesis stimulants; Factor IX stimulants; Factor VII stimulants; Granulocyte macrophage colony stimulating factor agonists; Immunomodulators; Immunostimulants; Immunosuppressants; Interferon alpha stimulants; Interferon gamma stimulants; Interleukin 10 stimulants; Interleukin 11 stimulants; Interleukin 2 stimulants; Interleukin 3 stimulants; Interleukin 4 receptor agonists; Interleukin 6 receptor modulators; Osteogenesis stimulants; Ovarian follicle stimulants; Somatotropin receptor agonists; Thrombopoietin stimulants; Thyrotropin releasing hormone stimulants; Transforming growth factor beta3 stimulants; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors; Tumour necrosis factor stimulants; Vascular endothelial growth factor A inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Anaemia; Bone disorders; Cancer; Haematological disorders; Immunological disorders; Infertility; Inflammation; Mouth disorders; Neutropenia; Rheumatic disorders; Skin disorders; Somatotropin deficiency; Thyroid cancer; Viral infections; Xenotransplant rejection

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for research development in Anaemia in South Korea
  • 28 Jul 2019 No recent reports of development identified for research development in Bone-disorders in South Korea
  • 28 Jul 2019 No recent reports of development identified for research development in Cancer in South Korea
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top